Model N Introduces New Rebate Enhancement, as Pharma Companies Prepare for Impact From the Inflation Reduction Act
Model N Introduces New Rebate Enhancement, as Pharma Companies Prepare for Impact From the Inflation Reduction Act
New Medicare Part D inflation rebate enhancement helps pharma manufacturers manage pricing reforms
新的Medicare D部分通胀回扣增强措施可帮助制药制造商管理定价改革
SAN MATEO, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Model N (NYSE: MODN), the leader in revenue optimization and compliance has introduced a critical product enhancement that supports evolving compliance needs around the Inflation Reduction Act (IRA). The company has introduced a new Medicare Part D inflation rebate-per-unit, ensuring pharma manufacturers remain compliant with impending IRA regulation and avoid significant revenue loss.
加利福尼亚州圣马特奥，2024年5月7日（GLOBE NEWSWIRE）——收入优化与合规领域的领导者Model N（纽约证券交易所代码：MODN）推出了一项关键产品增强措施，以支持围绕《通货膨胀降低法》（IRA）不断变化的合规需求。该公司推出了新的每单位Medicare D部分通货膨胀回扣，确保制药制造商遵守即将出台的IRA法规，避免重大收入损失。
"The Inflation Reduction Act introduces sweeping changes for drug pricing and Medicare programs, and our goal is to empower customers to stay ahead of these shifts," said Suresh Kannan, Chief Product Officer at Model N. "As our life sciences customers prepare for new reforms and regulatory changes, Model N's latest product innovations address a critical market need by providing the capabilities necessary to calculate and process complex Medicare Part D inflation rebates."
Model N首席产品官苏雷什·坎南说：“《通货膨胀降低法》对药品定价和医疗保险计划进行了全面的变革，我们的目标是使客户能够在这些变化中保持领先地位，在我们的生命科学客户为新的改革和监管变化做准备之际，Model N的最新产品创新通过提供计算和处理复杂的Medicare D部分通胀回扣所需的能力来满足关键的市场需求。”
According to Model N's 2024 State of Revenue Report, pharmaceutical executives are preparing for a significant revenue impact from the IRA. The law aims to lower prescription drug costs for Medicare beneficiaries through provisions allowing the program to negotiate prices for certain high-cost drugs and requiring manufacturers to pay rebates for any price changes higher than the inflation rate. Effective for Medicare Part B and D drugs, manufacturers must calculate inflation penalties based on pricing increases over the designated benchmark periods.
根据Model N的2024年收入状况报告，制药业高管正在为IRA的重大收入影响做准备。该法律旨在通过允许该计划谈判某些高成本药物的价格并要求制造商为任何高于通货膨胀率的价格变动支付回扣的条款，降低医疗保险受益人的处方药成本。对Medicare B部分和D部分药物有效，制造商必须根据指定基准期内的价格上涨来计算通货膨胀罚款。
Model N's new inflation rebate feature empowers customers to calculate Medicare Part D inflation rebate-per-unit, ensuring compliance with the upcoming IRA regulation set to take effect in 2025. Coupled with Model N's Government Pricing, Payer Management, Provider Management, and Validata solutions, customers gain a unified, end-to-end process to manage pricing strategy, calculate fees, and issue rebate payments in compliance with IRA guidance.
Model N的新通胀回扣功能使客户能够计算每单位的Medicare D部分通货膨胀回扣，从而确保遵守即将于2025年生效的IRA法规。再加上Model N的政府定价、付款人管理、提供商管理和Validata解决方案，客户将获得统一的端到端流程，按照IRA指南管理定价策略、计算费用和发放返利。
The company is committed to ensuring that pharma customers are equipped with the most up-to-date technology to comply with IRA guidance, which will continue to evolve into 2026. With continual enhancements to its suite of life sciences cloud solutions, Model N ensures pharma customers can nimbly adapt to evolving regulations while optimizing revenue.
该公司致力于确保制药客户配备最新的技术，以遵守IRA指导方针，该指导方针将持续发展到2026年。通过不断增强其生命科学云解决方案套件，Model N确保制药客户能够灵活地适应不断变化的法规，同时优化收入。
For more information on Model N's latest product innovations, visit
有关 Model N 最新产品创新的更多信息，请访问
###
###
About Model N
Model N is the leader in revenue optimization and compliance for pharmaceutical, medtech and high-tech innovators. Our intelligent platform powers your digital transformation with integrated technology, data, analytics, and expert services that deliver deep insight and control.
关于 Model N
Model N是制药、医疗技术和高科技创新者收入优化和合规方面的领导者。我们的智能平台利用集成的技术、数据、分析和专家服务，为您的数字化转型提供深刻的见解和控制。
Our integrated cloud solution is proven to automate pricing, incentive and contract decisions to scale business profitably and grow revenue. Model N is trusted across more than 120 countries by the world's leading pharmaceutical, medical technology, semiconductor, and high-tech companies, including Johnson & Johnson, AstraZeneca, Stryker, Seagate Technology, Broadcom, and Microchip Technology. For more information, visit .
事实证明，我们的集成云解决方案可以自动进行定价、激励和合同决策，从而实现业务盈利并增加收入。Model N在120多个国家受到世界领先的制药、医疗技术、半导体和高科技公司的信任，包括强生、阿斯利康、史赛克、希捷科技、博通和微芯科技。欲了解更多信息，请访问。
CONTACT: Public Relations BLASTmedia modeln@blastmedia.com Investor Relations Carolyn Bass investorrelations@modeln.com
联系人：公共关系 BlastMedia modeln@blastmedia.com 投资者关系 Carolyn Bass investorrelations@modeln.com